Welcome to our dedicated page for Tempest Therapeutics SEC filings (Ticker: TPST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tempest Therapeutics, Inc. filings document material-event disclosures for a clinical-stage biotechnology company developing CAR-T cell therapy and small-molecule product candidates. The company’s 8-K filings include Regulation FD presentations, press releases on TPST-2003 clinical data, annual financial results, business updates, and exhibits describing corporate presentations and pipeline activity.
The filing record also covers capital-structure and governance matters, including Nasdaq-listed common stock, Series A Junior Participating Preferred Purchase Rights, a limited-duration stockholder rights plan, equity incentive plan amendments, and listing-compliance notices. Material agreement disclosures include the completed acquisition of dual-targeting CAR-T assets and related common stock consideration.
Tempest Therapeutics is registering for resale up to 8,268,495 shares of its common stock issued to sellers in the Asset Purchase Agreement. The registration covers shares issued in connection with the Acquisition and permits the named selling stockholders and their permitted transferees to offer or sell the Shares from time to time.
The prospectus states we will not receive any proceeds from resale by the selling stockholders. The percentage ownership calculations are based on 14,344,034 shares outstanding as of March 25, 2026. Sales may occur in public or private transactions, at prevailing market prices or negotiated prices.
Tempest Therapeutics, Inc. reported that Corporate Controller Justin Trojanowski received a grant of employee stock options for 22,000 shares of common stock. The options have an exercise price of $1.64 per share and expire on March 30, 2036.
According to the vesting terms, 25% of the options will vest on March 31, 2027, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, his reported holdings in these options total 22,000 derivative securities, all held directly.
Tempest Therapeutics, Inc. reported that Chief Financial Officer Nicholas Maestas received a grant of employee stock options covering 140,000 shares of common stock at an exercise price of $1.64 per share. These options expire on March 30, 2036 and are held as a direct ownership position.
According to the vesting terms, 25% of the total shares will vest on March 31, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on Maestas’s continued service. Following this grant, he holds 140,000 options in this award.
Tempest Therapeutics, Inc. received an updated ownership report from several Versant-managed funds on Schedule 13D/A Amendment No. 7. The amendment reflects dilution of their stakes after the company sold additional common shares.
Versant Venture Capital VI, L.P. now reports beneficial ownership of 16,149 shares, or 0.1% of Tempest’s common stock. Versant Vantage II, L.P. reports 162,972 shares, or 1.1%. Versant Venture Capital IV, L.P. reports 90,084 shares, or 0.6%, and Versant Side Fund IV, L.P. reports 567 shares. Versant Ventures IV, LLC reports 90,651 shares, or 0.6%. Percentages are based on 14,344,034 shares outstanding as of March 25, 2026, per Tempest’s Form 10-K.
Tempest Therapeutics, Inc. is registering the resale of up to 2,777,781 shares of its common stock by selling stockholders.
The registration covers shares issued in a March 20, 2026 private placement (including 462,964 issued shares, 925,927 Series A Warrant shares, 925,927 Series B Warrant shares and 462,963 Pre-Funded Warrant shares). The company will not receive proceeds from resale of these shares. Shares outstanding were 14,344,034 as of March 30, 2026.
Tempest Therapeutics, Inc. is registering for resale up to 8,268,495 shares of its common stock on behalf of selling stockholders who received the shares under an Asset Purchase Agreement.
The prospectus states the Shares were issued in connection with the acquisition of CAR-T and related assets from Erigen LLC and Factor Bioscience Inc.; the company will not receive proceeds from resales. The prospectus discloses 14,344,034 shares outstanding as of March 25, 2026 and cites a closing market price of $1.73 per share on March 27, 2026. The registration statement is a shelf Form S-3 registration enabling resale "from time to time" by the named selling stockholders and any permitted transferees.
Tempest Therapeutics, Inc. is a clinical-stage oncology company focused on dual‑targeting CAR‑T cell therapies and first‑in‑class small molecules for difficult cancers and immunology indications.
In February 2026, Tempest closed an all‑stock acquisition of several dual‑targeting CAR‑T programs from Erigen and Factor, issuing 8,268,495 common shares and obtaining global rights outside Greater China, India, Turkey and Russia. Lead CAR‑T asset TPST‑2003, an autologous CD19/BCMA therapy for relapsed or refractory multiple myeloma, has shown early but striking activity, including a 100% complete response rate (6/6) in the REDEEM‑1 Phase 1/2a trial and a 100% overall response rate (25/25) across REDEEM‑1 and an investigator‑initiated trial.
Amezalpat, a selective oral PPARα antagonist for first‑line unresectable or metastatic hepatocellular carcinoma, delivered a six‑month median overall survival improvement (21 vs. 15 months) and a hazard ratio of 0.65 in a randomized global Phase 1b/2 study, and has received FDA orphan drug and Fast Track designations as well as EMA orphan drug status. Tempest plans a pivotal Phase 3 trial via partners, while advancing TPST‑1495 into a National Cancer Institute‑funded Phase 2 study in familial adenomatous polyposis and progressing allogeneic and in vivo CAR‑T candidates. As of March 25, 2026, Tempest had 14,344,034 common shares outstanding and a non‑affiliate equity market value of about $30.1 million as of June 30, 2025.
Tempest Therapeutics reported full-year 2025 results and a broad clinical update. The company ended 2025 with $7.7 million in cash and cash equivalents, down from $30.3 million a year earlier, reflecting operating cash use partly offset by equity offerings.
Net loss for 2025 was $26.3 million, or $6.33 per share, compared with $41.8 million and $19.50 in 2024, as research and development expenses fell to $12.6 million from $28.5 million after reprioritizing efforts. General and administrative expenses were $14.0 million, slightly above $13.6 million in 2024 due to one-time separation costs.
Strategically, Tempest completed an all-stock acquisition of dual-targeting CAR‑T assets from Factor Bioscience, including lead program TPST‑2003, which showed a 100% complete response rate in six efficacy‑evaluable rrMM patients in the REDEEM‑1 Phase 1/2a trial with a favorable safety profile. The company also advanced amezalpat and TPST‑1495 with multiple orphan and Fast Track designations and outlined plans for a potential U.S. registrational study of TPST‑2003 and new Phase 2 trials in 2026.